Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

This trial evaluated the efficacy and safety of Johnson & Johnson’s (J&J) Akeega, which includes Zejula (niraparib), a highly ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of ...

Future Oncol. 2015;11(1):91-106. Abiraterone was investigated in Phase I/II study in chemotherapy-naive CRPC patients: in this trial, a decline in PSA of ≥50% was observed in 67% of patients, a ...

Aim: To identify factors predicting primary resistance to new-generation hormonal agents (NHAs), abiraterone acetate and enzalutamide in patients with castration-resistant prostate cancer (CRPC ...